Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Takara Bio Inc. ( (JP:4974) ) has shared an announcement.
Takara Bio Inc. has announced its acquisition of ViSpot, Inc., a startup specializing in viral safety evaluation services in Japan. This strategic move is set to enhance Takara Bio’s quality testing capabilities and expand its one-stop CDMO services, addressing a significant gap in the domestic market for biopharmaceutical safety evaluations, and is expected to generate synergies by integrating ViSpot’s expertise with Takara’s existing technologies.
More about Takara Bio Inc.
Takara Bio Inc. operates within the biopharmaceutical industry, providing comprehensive CDMO services for the development, manufacturing, and quality testing of biopharmaceuticals, particularly focusing on cell and gene therapy products. The company is expanding its services to include antibody drug development and manufacturing, utilizing proprietary technology and large-scale facilities in Japan.
YTD Price Performance: -3.14%
Average Trading Volume: 205,361
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: Yen122.5B
See more data about 4974 stock on TipRanks’ Stock Analysis page.
